Bibliography
- LANGTON-WEBSTER B: Outlook for anti-angiogenesis therapy in cancer. Decision Resources, Inc. (2000) 1 3:1–16.
- PHARMACOR, ONKOS: Angiogenesis inhibition in cancer therapy. Decision Resources, Inc. (2000) :Study #43.
- VARNER JA: The role of vascular cell integrins c133 and avP5 in angiogenesis. In: Regulation of Angiogenesis. Goldberg ID, Rosen EM (Ed.), Birkhauser Verlag, Basel, Switzerland (1997):361–390.
- GASPARINI G, BROOKS PC, BIGANZOLI E et al.: Vascular integrin a„133: a new prognostic indicator in breast cancer. Clin. Cancer Res. (1998) 4:2625–2634.
- BROOKS PC, CLARK RAF, CHERESH DA: Requirement for vascular integrin av133 for angiogenesis. Science (1994) 264:569–571.
- BROOKS PC, MONTGOMERY AMP, ROSENFELD M et al: Integrin avi33 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79:1157–1164.
- GLADSON CL, CHERESH DA: Glioblastoma expression of vitronectin and the av133 integrin. j Clin. Invest. (1991) 88:1924–1932.
- GLADSON CL, HANCOCK S, ARNOLD MM, FAYE-PETERSEN OM, CASTLEBERRY RP, KELLY DR: Stage-specific expression of integrin av133 in neuroblastic tumors. Am. J. Pathol. (1996) 1 48 (5):1423–1434.
- KNOTT JCA, MAHESPARAN R, GARCIA-CABRERA I et al: Stimulation of ex tracellular matrix components in the normal brain by invading glioma cells. Int. J. Cancer (1998) 75:864–872.
- ISIK FF, GIBRAN NS, JANG YC, SANDELL L, SCHWARTZ SM: Vitronectin decreases microvascular endothelial cell apoptosis. J. Cell. Physiol. (1998) 175:149–155.
- UHM JH, DOOLEY NP, KYRITSIS AP, RAO JS, GLADSON CL: Vitronectin, a glioma-derived ex tracellular matrix protein, protects tumor cells from apoptotic death. Clin. Cancer Res. (1999) 5:1587–1594.
- SORBERA LA, GRAUL A, CASTANER J: Cilengitide. Drugs Future (2000) 25(7):674–678.
- CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000- September 2000. Exp. Opin. Ther. Patents (2000) 11(0: 77–114.
- HOLZEMANN G: Recent advances in a133 integrin inhibitors. IDrugs (2001) 4(1):72–81.
- CARRON CP, MEYER DM, PEGG JA et al.: A p eptidomi-metic antagonist of the integrin a„133 inhibits lzydig cell tumor growth and the development of hypercal-cemia of malignancy. Cancer Res. (1998) 58:1930–1935.
- BROOKS PC, STROMBLAD S, KLEMKE R, VISSCHER D, SARKAR FH, CHERESH DA: Anti-integrin c33 blocks human breast cancer growth and angiogenesis in human skin. J Clin. Invest. (1995) 96:1815–1822.
- PAGET S: The distribution of secondary growths in cancer of the breast. Lancet (1889) 1:571–573.
- FIDLER IJ: Modulation of the organ microenvironment for the treatment of cancer metastasis. J Natl. Cancer Inst. (1995) 84:1588–1592.
- PASQUALINI R, RUOSLAHTI E: Organ targeting in vivo using phage display peptide libraries. Nature (1996) 380:364–366.
- ARAP W, PASQUALINI R, RUOSLAHTI E: Cancer treatment by targeted drug delivery to tumor vascula-ture in a mouse model. Science (1998) 279:377–380.
- BADER BL, RAYBURN H, CROWLEY D, HYNES RO: Extensive vasculogenesis, angiogenesis and organo-genesis precede lethality in mice lacking all av integrins. Cell (1998) 95:507–519.
- MEREDITH JE, FAZELI B, SCHWARTZ MA: The extracel-lular matrix as a cell survival factor. Mol. Biol. Cell (1993) 4:953–961.
- MONTGOMERY AMP, REISFELD RA, CHERESH DA: Integrin av133 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc. Natl. Acad. Sci. USA (1994) 91 :8856–8860.